TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID-19
Posted: 4 June 2020 | Arsalan Azimi (Shiraz University of Medical Sciences) | 2 comments
Arsalan Azimi explains why inhibiting TMPRSS2 with clinically proven protease blockers could work as a therapeutic strategy against COVID-19.
Read the research – click here.
Related topics
Disease Research, Drug Repurposing, Drug Targets, Research & Development
Related conditions
Coronavirus, Covid-19
Thank you, Arsalan Azimi,
DOES TMPRSS2 INHIBIT, COMPLETELY DISCONTINUES SARS-CoV-2VIRUS INTAKE INTO THE CELL?
WHAT HAPPENS WITH THE INCOME BY THE ENDOSOMAL VIA?